Human VIP-α: an emerging biologic response modifier to treat primary pulmonary hypertension

References

• Fishman AP. Primary pulmonary arterial hypertension: a look back. J. Am. Coll. Cardiol. 43(Suppl. 12), 2S–4S (2004).
   Google Scholar
• Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur. Respir. J. 22, 358–363 (2003).
   PubMed Web of Science ®Google Scholar
• Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 157, 219–229 (1998).
   PubMed Web of Science ®Google Scholar
• Damas JK, Otterdal K, Yndestad A et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110, 999–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Nagaya N. Drug therapy of primary pulmonary hypertension. Am. J. Cardiovasc. Drugs 4, 75–85 (2004)
   Google Scholar
• Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 111, 1339–1346 (2003).
   PubMed Web of Science ®Google Scholar
• Keith IM. The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol. Res. 49, 519–537 (2000).
   PubMed Web of Science ®Google Scholar
• Busto R, Prieto JC, Bodega G, Zapatero J, Carrero I. Immuno-histochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 21, 265–269 (2000).
   PubMed Web of Science ®Google Scholar
• Busto R, Carrero I, Guijarro LG et al. Expression, pharmacological, and functional evidence for PACAP/VIP receptors in human lung. Am. J. Physiol. 277, L42–L48 (1999).
   Google Scholar
• Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans. Assoc. Am. Physicians 97, 304–310 (1984).
   PubMedGoogle Scholar
• Greenber B, Rhoden K, Barnes PJ. Relaxant effects of vasoactive intestinal peptide and peptide histidine isoleucine in human and bovine pulmonary arteries. Blood Vessels 24, 45–50 (1987).
   Google Scholar
• Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Res. 56, 249–290 (2004).
   Google Scholar
• Thom SM, Hughes AD, Goldberg P, Martin G, Schachter M, Sever PS. The actions of calcitonin gene related peptide and vasoactive intestinal peptides as vasodilators in man in vivo and in vitro. Br. J. Clin. Pharmacol. 24, 139–144 (1987).
   PubMed Web of Science ®Google Scholar
• Greenberg B, Rhoden K, Barnes PJ. Endothelium-dependent relaxation of human pulmonary arteries. Am. J. Physiol. 252, H434-H438 (1987).
   Google Scholar
• Leys K, Morice AH, Madonna O, Sever PS. Autoradiographic localization of VIP receptors in human lung. FEBS Lett. 199, 198–202 (1986).
   Google Scholar
• Dey RD, Shannon WA Jr, Said SI. Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects. Cell Tissue Res. 220, 231–238 (1981).
   PubMed Web of Science ®Google Scholar
• Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptides? Faseb J. 18, 1325–1334 (2004).
   Google Scholar
• Söderman C, Eriksson LS, Juhlin-Dannfelt A, Lundberg JM, Broman L, Holmgren A. Effect of vasoactive intestinal polypeptide (VIP) on pulmonary ventilation-perfusion relationships and central haemodynamics in healthy subjects. Clin. Physiol. 13, 677–685 (1993).
   PubMedGoogle Scholar
• Delgado M. Inhibition of interferon (IFN) gamma-induced Jak-STAT1 activation in microglia by vasoactive intestinal peptide: inhibitory effect on CD40, IFN-induced protein-10, and inducible nitric-oxide synthase expression. J. Biol. Chem. 278, 27620–27629 (2003).
   PubMed Web of Science ®Google Scholar
• Cox CP, Linden J, Said SI. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 5, 325–328 (1984).
   PubMed Web of Science ®Google Scholar
• Konttinen Y, Imai S, Suda A. Neuropeptides and the puzzle of bone remodeling. State of the art. Acta Orthop. Scand. 67, 632–639 (1996).
   PubMed Web of Science ®Google Scholar
• Zwerina J, Landsteiner H, Leitgeb U et al. The influence of VIP and epoprostenol on platelet CD62P expression and primary haemostasis in vitro. Platelets 15, 55–60 (2004).
   PubMed Web of Science ®Google Scholar
• Gozes I, Furman S. Potential clinical applications of vasoactive intestinal peptide: a selected update. Best Pract. Res. Clin. Endocrinol. Metab. 18, 623–640 (2004).
   PubMedGoogle Scholar
• Chongsrisawat V, Ampai S, Chotivitayatarakorn P, Sirisopikul T, Poovorawan Y. Relationship between vasoactive intestinal peptide and intrapulmonary vascular dilatation in children with various liver diseases. Acta Paediatr. 92, 1411–1414 (2003).
   Google Scholar
• Eriksson LS, Hagenfeldt L, Mutt V, Wahren J. Influence of vasoactive intestinal polypeptide (VIP) on splanchnic and central hemodynamics in healthy subjects. Peptides 10, 481–484 (1989).
   Google Scholar
• Virgolini I, Raderer M, Kurtaran A et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331, 1116–1121 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidt DT, Rühlmann E, Waldeck B et al. The effect of the vasoactive intestinal polypeptide agonist Ro 25–1553 on induced tone in isolated human airways and pulmonary artery. Naunyn-Schmiedeberg’s Arch. Pharmacol. 364, 314–320 (2001).
   Google Scholar
• Gao X-p, Noda Y, Rubinstein I, Paul S. Vasoactive intestinal peptide encapsulated in liposomes: effects on systemic arterial blood pressure. Life Sci. 54, PL247–PL252 (1994).
   Google Scholar
• Suzuki H, Noda Y, Gao X-P et al. Encapsulation of VIP into liposomes restores vasorelaxation in hypertension in situ. Am. J. Physiol. 271, H282–H287 (1996).
   PubMed Web of Science ®Google Scholar
• Séjourné F, Suzuki H, Alkan-Önyüksel H, Gao X-p, Ikezaki H, Rubinstein I. Mechanisms of vasodilation elicited by VIP in sterically stabilized liposomes in vivo. Am. J. Physiol. 273, R287–R292 (1997).
   PubMed Web of Science ®Google Scholar
• Gololobov G, Noda Y, Sherman S, Rubinstein I, Baranowska-Kortylewicz J, Paul S. Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther. 285, 753–758 (1998).
   Google Scholar
• Ikezaki H, Paul S, Alkan-Önyüksel H, Patel M, Gao X-P, Rubinstein I. Vasodilation elicited by liposomal VIP is unimpeded by anti-VIP antibody in hamster cheek pouch. Am. J. Physiol. 275, R56–R62 (1998).
   Google Scholar
• Ikezaki H, Alkan-Önyüksel H, Rubinstein I. Liposomal VIP attenuates phenylephrine- and angiotensin II-induced vasoconstriction in vivo. Am. J. Physiol. 275, R588-R595 (1998).
   Google Scholar
• Önyüksel H, Ikezaki H, Patel M, Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res. 16, 155–160 (1999).
   PubMed Web of Science ®Google Scholar
• Ikezaki H, Patel M, Önyüksel H, Akhter SR, Rubinstein I. Exogenous calmodulin potentiates vasodilation elicited by phospholipid-associated VIP in vivo. Am. J. Physiol. 276, R1359–R1365 (1999).
   Google Scholar
• Séjourné F, Rubinstein I, Suzuki H, Alkan-Önyüksel H. Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm. Res. 14, 362–365 (1997).
   PubMed Web of Science ®Google Scholar
• Rubinstein I, Patel M, Ikezaki H, Dagar S, Önyüksel H. Conformation and vasoreactivity of VIP in phospholipid micelles: effects of calmodulin. Peptides 20, 1497–1501 (1999).
   Google Scholar
• Önyüksel H, Bodalia B, Sehti V, Dagar S, Rubinstein I. Surface-active properties of vasoactive intestinal peptide. Peptides 21, 419–423 (2000).
   Google Scholar
• Tsueshita T, Gandhi S, Önyüksel H, Rubinstein I. Phospholipids modulate the biophysical properties and vasoactivity of PACAP(1–38). J. Appl. Physiol. 93, 1377–1383 (2002).
   Google Scholar
• Yeomans DC, Önyüksel, Dagar S, Ikezaki H, Lu Y, Rubinstein I. Conformation-dependent effects of VIP on nociception in rats. Peptides 24, 617–622 (2003).
   Google Scholar
• Önyüksel H, Ashok B, Dagar S, Sethi V, Rubinstein I. Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity. Peptides 24, 281–286 (2003).
   PubMed Web of Science ®Google Scholar
• Ashok B, Rubinstein I, Tsueshita T, Önyüksel H. Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP1–38 in pegylated phospholipid micelles. Peptides 25, 1253–1258 (2004).
   PubMedGoogle Scholar
• Sethi V, Önyüksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol. 391, 377–395 (2005).
   PubMed Web of Science ®Google Scholar
• Refai E, Jonsson C, Andersson M et al. Biodistribution of liposomal 131I-VIP in rat using gamma camera. Nucl. Med. Biol. 26, 931–936 (1999).
   PubMed Web of Science ®Google Scholar
• Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319–328 (2003).
   PubMed Web of Science ®Google Scholar
• Otto C, Hein L, Brede M et al. Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110, 3245–3251 (2004).
   Google Scholar